Neuromuscular Electrical Stimulation (NMES) — NCD 175 | CMS Coverage Update

CMS modified NCD 175 governing Medicare coverage of Neuromuscular Electrical Stimulation (NMES), effective March 7, 2026. Here's what billing teams need to know.

The Centers for Medicare & Medicaid Services updated National Coverage Determination 175, which controls Medicare reimbursement for NMES across two distinct clinical applications: treatment of muscle atrophy and functional electrical stimulation (FES) for walking in spinal cord injury (SCI) patients. This modification affects physical therapy practices, rehabilitation facilities, durable medical equipment suppliers, and any setting billing for NMES services under Medicare. The policy does not list specific CPT or HCPCS codes — which creates its own documentation challenge for your billing team.

Quick-Reference Table

CMS Neuromuscular Electrical Stimulation Coverage Criteria and Medical Necessity Requirements 2026

NCD 175 is the National Coverage Determination governing Medicare coverage of NMES across all settings. The policy draws a hard line between two types of devices and two types of clinical indications — and conflating them in your documentation is a fast path to claim denial.

Type 1: Resting-state NMES for muscle atrophy. Coverage applies when NMES is used to treat disuse atrophy where the nerve supply to the muscle remains intact — including the brain, spinal cord, and peripheral nerves — and the atrophy has a non-neurological cause. CMS's examples are concrete: casting or splinting of a limb, contracture from burn scarring, and hip replacement surgery (coverage runs only until orthotic training begins). The medical necessity standard here is intact nerve supply plus a disuse etiology. If your documentation doesn't establish both, expect denial.

Type 2: FES for walking in SCI patients. This is where the coverage policy gets genuinely complex and where your exposure is highest. Functional electrical stimulation (FES) — the NMES subtype that activates paralyzed or weak muscles in sequence to enable walking — is covered for SCI patients only when a specific, gate-kept set of criteria is met. The prior authorization risk here is real even when prior auth isn't explicitly required, because CMS can deny on medical necessity grounds post-claim if your documentation doesn't map to the nine criteria listed below.

The FES training requirement alone is a billing trigger many teams miss: the patient must complete at least 32 physical therapy sessions with the device over a three-month period before coverage for the device itself is established. That training must be one-on-one, directly performed by a physical therapist — not supervised, not delegated. The goal of that therapy must be explicitly documented as training the patient to use NMES/FES for walking, not to reverse or retard muscle atrophy. That distinction matters on audit.

CMS also restricts the settings where FES training can be billed under this coverage policy. The only approved settings are inpatient hospitals, outpatient hospitals, comprehensive outpatient rehabilitation facilities (CORFs), and outpatient rehabilitation facilities. If your practice doesn't fall into one of those categories, you're billing outside the covered setting — and reimbursement will be denied regardless of how well the patient meets clinical criteria.

CMS NMES Exclusions and Non-Covered Indications

CMS is explicit about when FES for walking will not be covered in SCI patients. These are hard exclusions — not judgment calls, not "consider carefully" situations. If your patient has any of the following, the claim is not covered:

Document the absence of these contraindications in your medical records. A claim that doesn't demonstrate the treating physician screened for these exclusions is vulnerable on audit, even if the patient doesn't actually have any of them.

On the atrophy side, the policy is equally clear: NMES for atrophy is not covered when the nerve supply is not intact. Neurological causes of atrophy — including those stemming from brain, spinal cord, or peripheral nerve compromise — are outside the coverage boundary for the atrophy indication. This is counterintuitive to some clinicians, so make sure your documenting providers understand it.

Coverage Indications at a Glance

CMS NMES Billing Guidelines and Action Items 2026

These are the steps your billing and clinical documentation teams need to take before March 7, 2026.

CPT, HCPCS, and ICD-10 Codes for NMES Under NCD 175

The real issue here is that CMS NCD 175 does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. That's not an oversight — NCDs often operate as coverage frameworks that apply across a range of codes rather than specifying them directly.

Covered Codes

Practical Guidance on Codes

Your Medicare Administrative Contractor (MAC) is the right place to resolve the code question. MACs publish local coverage articles (LCAs) that accompany NCDs and typically specify the HCPCS codes for NMES devices (commonly found in the E-code range for DME) and the CPT codes for PT training sessions. The absence of codes in the NCD itself means the national coverage criteria in NCD 175 apply to whatever codes your MAC has mapped to NMES and FES services.

Check with your MAC before March 7, 2026, to confirm which codes they've associated with NCD 175 coverage and whether any local coverage determination (LCD) supplements or constrains what CMS has defined nationally.